4.1 Article Data Paper

Datasets of Iso-Seq transcripts for decoding transcriptome complexity in four Leishmania species

Journal

DATA IN BRIEF
Volume 52, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.dib.2023.109838

Keywords

RNA sequencing; Transcriptomics; L. braziliensis; L. donovani; L. infantum; L. major

Ask authors/readers for more resources

The Iso-Seq technology based on PacBio sequencing was used to generate high-quality, full-length transcripts of Leishmania species. The analysis of these transcripts provides insights into gene expression regulation and potential therapeutic targets for leishmaniasis and related parasitic diseases.
The Iso-Seq technology, based on PacBio sequencing, enables the generation of high-quality, full-length transcripts, pro-viding insights into transcriptome complexity. In this study, total RNA from promastigotes of four Leishmania species (Leishmania braziliensis, Leishmania donovani, Leishmania infantum and Leishmania major ) was sequenced using Single Molecule, Real-Time (SMRT) Sequencing (PacBio) methodology. The Iso-seq transcripts were categorized as either complete or truncated according to the presence or absence of the Spliced-Leader (SL) sequence at their 5 '-end, respectively. Moreover, only transcripts having a poly-A+ at their 3'-end were considered. Supplied datasets represent valuable information that may help to uncover novel transcripts and alternative splicing events in a parasite that regulates its gene expression at the post-transcriptional level. A better knowledge of gene expression regulation in Leishmania will open avenues for the development of new drugs to treat leishmaniasis, a devastating disease that has worldwide distribution. Additionally, the bioinformatics pipeline followed here may guide the analysis of Iso-Seq data derived from related try- panosomatids like Trypanosoma cruzi (Chagas disease agent) and Trypanosoma brucei (sleeping disease).(c) 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available